Barclays BCS
$22.33 −$0.49 (-2.15%)
Market closed · Nov 7, 9:10 am ET · Last extended-hours $22.47 +0.63%
Open$22.33
Prev close$22.82
Day range$22.32 – $22.73
Volume6.83M
Market cap$74.23B
P/E (TTM)8.3
Dividend yield2.72%
BCS Stock News
Headlines matching Barclays or the BCS ticker, most recent first.
- Former Barclays CEO: The Clarity Act is really good for banks, and the largest and most successful banks will benefit from it.
- RBC Trims Price Target on Barclays to GBP5.50 From GBP5.75, Keeps Outperform Rating Positive
- Correct: Barclays Group 2Q Net Interest Income GBP3.92B
- U.S. Stocks Move | Barclays falls 5.6% in pre-market trading despite a 31% year-over-year increase in Q2 profit, as costs and impairments surge Positive
- OTS Holdings: General Announcement-Proposed acquisition by BCS Development Pte. Ltd.
- Barclays: U.S. 30-Year Treasury Yield Could Rise to 6% if Productivity Growth Continues to Accelerate Positive
- Barclays PLC increased its stake in Dongjiang Environmental by 12.7888 million shares at approximately HK$1.93 per share.
- Barclays (BCS.US) has appointed Ramin Naji as Head of Healthcare and Real Estate for the Asia-Pacific region.
- Morgan Stanley reportedly poaches a key executive from Barclays to serve as Vice Chairman of its Technology Investment Banking division.
- Barclays Maintains International Flavors & Fragrances(IFF.US) With Buy Rating, Cuts Target Price to $103 Negative
- Barclays Maintains Cardinal Health(CAH.US) With Buy Rating, Maintains Target Price $275
- Barclays Maintains ICG PLC(ICGUF.US) With Buy Rating, Cuts Target Price to $35.46 Negative
- Barclays Maintains Nova(NVMI.US) With Buy Rating, Cuts Target Price to $500 Negative
- Barclays Maintains SiTime(SITM.US) With Buy Rating, Maintains Target Price $850
- Barclays Maintains AUMOVIO SE(AMVIF.US) With Buy Rating, Cuts Target Price to $66.9 Negative
No comments yet — be the first to weigh in on BCS.
Sign in to join the discussion.